Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Varicella live attenuated vaccine is a viral vaccine developed by Weiguang Biological Products for the prevention of varicella (chickenpox). It contains a live, weakened form of the Varicella zoster virus (VZV). Upon subcutaneous administration, the vaccine mimics a natural infection to stimulate the production of neutralizing antibodies and activate T-cell mediated immunity, providing long-term protection against the virus. This vaccine is part of Weiguang's research and development pipeline as the company expands its portfolio beyond blood-derived products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on varicella live attenuated vaccine (Weiguang Biological Products).